Intrinsic Imaging provides imaging core lab services in support of gastroenterology and metabolic clinical trials. Sponsors draw on our subspecialty gastroenterologists, central endoscopy review and quantitative abdominal imaging to assess safety and efficacy in gastrointestinal, hepatobiliary, pancreatic, metabolic, renal and related abdominal and pelvic indications.
At Intrinsic Imaging, our Gastroenterology Imaging division brings together more than 35 board-certified, fellowship-trained gastroenterologists with expertise across a broad range of acute and chronic gastrointestinal conditions, including inflammatory bowel disease, ulcerative colitis, gastroesophageal reflux disease (GERD), short bowel syndrome, and gastrointestinal ulcerative disease. In these and other complex disorders, imaging and endoscopic evaluation can provide objective evidence of disease activity, progression, and therapeutic response.
Intrinsic Imaging supports gastroenterology endpoints across a comprehensive range of imaging and diagnostic modalities, including CT and high-resolution CT, low-dose and advanced CT techniques, MRI, endoscopy, and nuclear imaging with quantitative methodologies. Our teams work closely with sponsors from protocol development and imaging charter design through regulatory-ready data delivery to develop study-specific imaging strategies, qualify sites and readers, standardize acquisition, maintain image and endoscopy quality control, and conduct centralized independent review with quantitative assessment and adjudication.
By combining experienced gastroenterology specialists with disciplined central-review processes and consistent assessment methodologies, Intrinsic Imaging helps sponsors minimize inter-site and inter-reader variability across longitudinal timepoints, an essential consideration when imaging or endoscopic findings contribute to efficacy, safety, disease-activity, or exploratory biomarker endpoints. This scientific, clinical, and operational expertise supports complex gastroenterology clinical development programs from early-phase investigation through pivotal trials.